Clinical Trial Update: Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy [NA]

View source ↗

Summary

Clinical trial evaluating a larger dose of spironolactone for nonischemic cardiomyopathy; the study is reported as terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Nonischemic Cardiomyopathy

Drugs mentioned

• Aldactone (spironolactone)

Snippet

Sponsor: Hebei Medical University | Conditions: Heart Failure, Congestive | NA | Status: TERMINATED